Skip to content

THE SCIENCE NOTES

Complex Science, Simplified.

  • Diseases Guide
  • Cell and Molecular Biology
  • Anatomy and Physiology
  • Immunology
  • Protocols and Techniques
  • Food Science
  • Microbiology
  • Biotechnology
  • Biochemistry
  • Bacteriology
  • Cancer
  • Biology
  • News & Blogs
  • Contact Us
  • Privacy Policy
THE SCIENCE NOTES
  • Diseases Guide
  • Cell and Molecular Biology
  • Anatomy and Physiology
  • Immunology
  • Protocols and Techniques
  • Food Science
  • Microbiology
  • Biotechnology
  • Biochemistry
  • Bacteriology
  • Cancer
  • Biology
  • News & Blogs
  • Contact Us
  • Privacy Policy

Day: March 12, 2026

Infographic showing the mechanism of action of Teclistamab where the bispecific antibody binds BCMA on myeloma cells and CD3 on T cells to activate cytotoxic T-cell signaling and tumor cell killing.
Posted on March 12, 2026March 24, 2026 Cancer Immunology

Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results

Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more

Infographic showing BCMA-targeted therapies for multiple myeloma including bispecific antibody teclistamab, CAR-T cell therapy, and antibody-drug conjugate belantamab mafodotin.
Posted on March 12, 2026March 24, 2026 Cancer Immunology

BCMA-Targeted Therapies in Multiple Myeloma: Teclistamab vs CAR-T vs Antibody-Drug Conjugates

Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more

BCMA signaling pathway cartoon diagram showing NF-κB, PI3K-AKT, and MAPK pathways activated by BCMA in multiple myeloma cells
Posted on March 12, 2026March 24, 2026 Cancer Immunology

BCMA Signaling Pathway in Multiple Myeloma: Structure, Function and Therapeutic Targeting

BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more

A scientific table comparing five bispecific antibodies. The top rows show structural designs: a BiTE (Blinatumomab) and four IgG-like structures (Mosunetuzumab, Epcoritamab, Glofitamab, and Odronextamab). The bottom panel illustrates "Mechanism & Pharmacokinetics," showing tissue penetration, T-cell engagement levels, and PK curves for each molecule.
Posted on March 12, 2026April 3, 2026 Cancer Immunology

Bispecific Antibodies in Cancer Immunotherapy

Explore the structural design, mechanism of action, and clinical applications of bispecific antibodies in cancer immunotherapy for targeted tumor killing. Read more

Recent Posts

  • Cryo-Electron Microscopy (Cryo-EM): Principle, Techniques, and Steps
  • Peanut Allergy Prevention: Early Introduction & Lasting Protection
  • Human Nervous System: Divisions, Functions & Anatomy Guide
  • Cell Division: Foundations, Mechanisms, and Modern Research
  • ELISPOT Assay: Theory, Methodology, and Research Applications

🔥 Trending Now

  • 01 M1 and M2 Macrophage Polarization Protocol
  • 02 Health Impacts of Microplastics: A Complete Guide
  • 03 Entamoeba histolytica: Lifecycle and Diagnosis
Advertisement
March 2026
SMTWTFS
1234567
891011121314
15161718192021
22232425262728
293031 
« Feb   Apr »
Advertisement

Two things are infinite: the universe and human stupidity; and I'm not sure about the universe. - Albert Einstein

© 2026 THE SCIENCE NOTES / Powered by WordPress / Theme by Design Lab